Artificial Intelligence for
Life Science and Healthcare
We support biotech, pharma and medtech companies moving forward with artificial intelligence technology.
Clients
Services
Managing Director (CEO)
→ Profile
Dr. Paul von Bünau
-
The advent of artificial intelligence creates new opportunities and threats. Rather than jumping straight into ue cases, formulating a winning starts with asking: what could this new technology mean for us? We support you from initial orientation to execution and organizational change.
-
Progress in artificial intelligence opens new opportunities for organizations to create unique proprietary technology for strategic advantage. We support you from discovery, proof-of-value and design to building and operating AI-enabled solutions that deliver on their strategic intent.
-
“Value from data and AI” is easier said than done, as high-level narratives fail to connect with the nitty-gritty, and technical innovation must not mean business. Digging deeper, we identify tangible opportunities for portfolio companies, and realise their value quickly.
-
Market access and pricing is the crucial last-mile of bringing innovative health technology to patients. Dictated by the authorities’ requirements, this is an area abundant with mundane workflows perfectly suited to augmentation by AI. We accelerate your work with custom-built tools.
Senior Associate
julian.beimes@idalab.de
+49 173 6762781
Julian Beimes
-
Realising the potential of AI depends on an integrated strategy for regulatory compliance. To not get stuck between proof-of-concept and product, medical device and AI regulation, as well as data protection and market access must be addressed early on. We support you breaking through.
-
Despite their proximity to patients and data, turning medical devices’ privileged position into a strategic advantage can be challenging due to legacy technology, regulation, a tech-focused culture and established care models. We help you move forward.
Client stories
-
How a drug discovery startup used AI to read 10,000 papers and zero in on their ideal targets
-
How Matchpoint Therapeutics accelerated discovery by fusing siloed data into a unified pipeline
-
Scaling a precision drug dosing algorithm to millions of patients
Leading provider of dialysis products and services for CKD patients
-
Designing an AI-driven emerging technology radar for pharma R&D and M&A
Multinational pharma and diagnostics company
-
Accelerating market access for new therapies using Generative AI
Market access consulting firm with focus on rare diseases
-
Driving the transformation from Data Warehouse to Data Product team
Medical device manufacturer in the cardio-vascular space
What our clients say
-
![]()
“idalab have worked seamlessly with our research leaders to implement a target discovery engine that captures our unique insight but can be scaled across biological classes. Pragmatic and cutting-edge. Great team!”
Jonathan Montagu
CEO
HotSpot Therapeutics -
![]()
“It is a pleasure working with the idalab team on our data and machine learning pipeline. They are an outstanding strategic partner, collaborating seamlessly with our science team. Fast, clear communication, structured – yet always happy to adapt ad hoc, if necessary. We are looking forward to continuing the collaboration.”
Suresh Singh, PhD
SVP Computational Science
Matchpoint Therapeutics -
![]()
”Working with the idalab team was truly amazing and inspiring. Experienced as they are, they demonstrated all but telepathic abilities, immediately understanding our project’s requirements. Integrating data/AI and biology know-how, idalab helped us find innovative solutions to hard challenges: a true (and fun!) creative partnership. Highly recommended!”
Dr. Markus Rinecker
CMO/CFO
mbiomics
Newsletter